Introduction
============

Uterine cancer is the second most common malignancy in females and the incidence of this disease is only lower than that of breast cancer ([@b1-ol-0-0-8815]). According to a report released by the International Agency for Research on Cancer, \>300,000 women die from uterine cancer each year, and \>80% of them are from developing countries ([@b2-ol-0-0-8815]). In recent years, the incidence of uterine cancer shows an increasing trend in developing countries, especially in young women, incidence of this disease increases by 3% every year ([@b3-ol-0-0-8815]). So far, the mechanism of uterine cancer has not been completely elucidated. Therefore, the development of new biomarkers and effective treatment targets is the key to further improve the prognosis of uterine cancer. miRNAs are a class of highly conserved endogenous regulatory RNA molecules with a length of 18--26 bp. miRNAs bind to mRNA molecules transcribed from target genes and inhibit the its translation, ultimately regulating the expression of target genes ([@b3-ol-0-0-8815],[@b4-ol-0-0-8815]). Many miRNAs, such as miR-16, miR-155 and miR-223, were upregulated in uterine cancer tissues ([@b5-ol-0-0-8815]), expression of some other miRNAs, such as miR-143 and miR-145, decreased in uterine cancer tissues ([@b6-ol-0-0-8815]), indicating that miRNAs may be key players in uterine cancer. miR-222 is highly expressed in a variety of tumors, including breast ([@b7-ol-0-0-8815]), bladder ([@b8-ol-0-0-8815]), colon ([@b9-ol-0-0-8815]), glioblastoma ([@b10-ol-0-0-8815]), and pancreatic cancer ([@b11-ol-0-0-8815]). However, the role of miR-222 in uterine cancer is still unclear. Therefore, in this study, the expression of miR-222 in uterine cancer and adjacent tissues was detected by stem-loop RT-PCR to investigate the relationship between miR-222 expression and clinicopathological features of this disease, so as to explore the role of miR-222 in the occurrence and development of uterine cancer and its clinical significance.

Patients and methods
====================

Patients
--------

### Experimental data

A total of 66 patients with uterine cancer diagnosed by gynecological and pathological examination in Dongying People\'s Hospital (Dongying, China) were enrolled from March 2014 to October 2016. During surgical resection, uterine cancer and adjacent tissues were collected. Ages of patients ranged from 33 to 75 years. Among those patients, 27 patients had tumors \<4 cm in diameter and the remaining patients all had a tumor diameter ≥4 cm. No patients received radiotherapy or chemotherapy before admission. Uterine cancer histopathological types: squamous cell carcinoma in 53 cases, adenocarcinoma in 9 cases, adenosquamous carcinoma in 4 cases. Uterine cancer tissue differentiation degree: 9 cases in grade I, 19 cases in grade II and 38 cases in grade III. FIGO stage: 6 cases in stage I, 25 cases in stage II, 18 cases in stage III and 17 cases in stage IV. All patients or their families signed informed consent. This study was approved by the Ethics Committee of Dongying People\'s Hospital (Dongying, China).

### Reagents and instruments

Tissue total RNA extraction kit (BioLabs Technology Co., Ltd., Beijing, China), miRNA reverse transcription kit (GeneCopoeia, Inc., Rockville, MD, USA), fluorescence quantitative PCR kit SYBR-Green (Huaxia Yuanyang Technology Co., Ltd., Beijing, China), urea (Healthdream Biological Technology Co., Ltd., Wuhan, China), ABI 7500 fluorescence quantitative PCR instrument (Thermo Fisher Scientific, Inc., Waltham, MA, USA), quantitative spectrophotometer (Jiang Xue Technology Co., Ltd., Chongqing, China).

Method
------

### miR-222 expression analysis

Total RNA was extracted according to the manufacturer\'s instructions, and A260/A280 ratio was meaured using a quantitative spectrophotometer. Total RNA was reverse transcribed into cDNA in accordance with the instructions of miRNA reverse transcription kit. Reverse transcription system: 1 µg total RNA, 50 µM stem-loop RT primer, 2 U RNase inhibitor, 5 U M-MLV reverse transcriptase, and 0.5 µM dNTPs. Reaction conditions: 16°C for 30 min, 42°C for 30 min and 75°C for 15 min. All cDNA samples were stored at −20°C. This experiment was performed 3 times ([Table I](#tI-ol-0-0-8815){ref-type="table"}).

RT-qPCR reaction system (15 µl): 1 µl cDNA, 1X SYBR-Green I Mastermix, 0.5 µM miRNA specific forward primer, 0.5 µM universal reverse primer. Reaction conditions: 94°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 60 sec, and 72°C for 30 sec. With let-7a as endogenous control ([@b12-ol-0-0-8815]), the relative expression of miRNA was calculated automatically by RT-PCR instrument.

### Analysis of the specificity of miR-222 stem-loop RT-PCR

A total of 5 µg total RNA was used to isolate low molecular weight RNAs. After denaturing by 15% urea solution, miRNA precursor and mature miRNA were then separated by 8% PAGE. Stem-loop RT-PCR was then performed to detect miR-222. Reaction volume was 20 µl. First, 2 µg of total RNA, 1 µl of RT primer (stem-loop primer) and 1 µl of dNTPs were mixed, and DEPC water was added to make a volume of 14 µl. After denaturation at 65°C for 5 min, in the produced was kept on ice. Then 1 µl of reverse transcriptase AMV, 4 µl of buffer and 1 µl of RNase inhibitor were added. Reaction conditions were: 16°C for 30 min, followed by 60 cycles of 20°C for 30 sec, 42°C for 30 sec and 50°C for 1 sec, and 85°C for 10 min.

### Statistical analysis

Data were analyzed using SPSS 19.0 software (Beijing Xinmei Jiahong Technology Co., Ltd., Beijing, China). Measurement data were expressed as mean ± standard deviation, ANOVA was used for multiple group comparisons and the post hoc test was Dunnetts test. Survival analysis was performed using GraphPad Prism 5 with α=0.05 as standard.

Results
=======

### Establishment of stem-loop RT-PCR detection method

The product of miRNA amplification by stem-loop RT-PCR showed a single band after 8% PAGE. So stem-loop RT-PCR method can specifically amplify miR-222 ([Fig. 1](#f1-ol-0-0-8815){ref-type="fig"}).

As shown in [Fig. 2](#f2-ol-0-0-8815){ref-type="fig"}, after 8% PAGE, gray values of the bands derived from PCR reaction with 22 or 30 cycles were similar. PCR with 30 cycles provided a faint band, while PCR with 22 cycles failed to show this band. We speculated that low RNA recovery rate is the reason why amplification efficiency of mature miRNA was lower than total RNA amplification efficiency. Small RNA recovery efficiency was only 50%.

### miR-222 expression in uterine cancer and adjacent tissues

With let-7a as endogenous control, the relative expression levels of miR-222 in adjacent and uterine cancer tissues were 0.275±0.094 and 0.953±0.183, respectively. The expression level of miR-222 in adjacent tissues was significantly lower than that in uterine cancer tissues. The difference was statistically significant (p\<0.05) ([Fig. 3](#f3-ol-0-0-8815){ref-type="fig"}).

### Correlation between miR-222 expression and a variety of clinicopathological features of uterine cancer

The expression level of miR-222 was different in uterus cancer tissues with the different differentiation degrees. The expression level of miR-222 in grade III uterine cancer is obviously higher than that in grade I and II. The expression level of miR-222 was increased with the increased degree of malignancy. There was no significant correlation between miR-222 expression and age, tumor size, gross type, pathological type and FIGO stage (p\>0.05) ([Table II](#tII-ol-0-0-8815){ref-type="table"}).

### Correlation between miR-222 expression and prognosis

Follow-up study of 66 uterine cancer patients showed that the median survival time of miR-222 high expression uterine cancer patients was 21.4±0.8 months, while the median survival time of miR-222 low expression uterine cancer patients was 44.9±1.7 months. The expression level of miR-222 was significantly negatively correlated with the survival of uterine cancer patients (p\<0.05) ([Fig. 4](#f4-ol-0-0-8815){ref-type="fig"}).

Discussion
==========

Uterine cancer is the second most common malignancy in women, and its incidence is only lower than that of breast cancer ([@b13-ol-0-0-8815]). However, pathogenesis of uterine cancer has not been fully understood, leading to poor treatment outcomes as well as high recurrence and mortality rate ([@b14-ol-0-0-8815]). As a class of highly conserved endogenous regulatory RNAs, miRNAs bind to mRNAs transcribed from target genes to inhibit further translation, thereby regulating the expression of target genes and participating in a series of physiological and pathological processes ([@b15-ol-0-0-8815]). miRNA can play a role as oncogene or tumor suppressor gene in the occurrence and development of a tumor ([@b16-ol-0-0-8815]).

Analysis of the expression pattern of miRNAs in invasive cervical squamous cell carcinoma showed that most miRNAs were upregulated and only two were downregulated ([@b16-ol-0-0-8815]). The expression level of miR-127 is significantly correlated with lymph node metastasis ([@b17-ol-0-0-8815]). Some scholars found that in colon cancer tissues, miR-143 and miR-145 expression were significantly downregulated ([@b18-ol-0-0-8815],[@b19-ol-0-0-8815]). In addition, abnormal expression of a large number of miRNAs in solid tumors was observed, and most miRNAs, such as miR-21, miR-92 and miR-155, were usually upregulated ([@b20-ol-0-0-8815],[@b21-ol-0-0-8815]).

In recent years, studies have shown that the expression level of miR-222 is increased to varying degrees in tumor tissue or tumor cell lines of different types of cancer ([@b22-ol-0-0-8815],[@b23-ol-0-0-8815]). miR-222 is involved in the occurrence and development of a variety of cancers, such as bladder cancer ([@b24-ol-0-0-8815]), prostate cancer ([@b25-ol-0-0-8815]), and melanoma ([@b26-ol-0-0-8815]). Among these cancers, target genes are usually tumor suppressor genes or pre-apoptotic factors. miR-222 inhibits cell apoptosis and participates in the occurrence and development of tumor through the regulation of expression of its target genes ([@b23-ol-0-0-8815]). Results of this study showed that the stem-loop RT-PCR can specifically amplify miRNA. miR-222 was significantly upregulated in uterine cancer tissue, suggesting that miR-222 may be involved in the occurrence and development of uterine cancer. It has been reported that miR-222 can regulate the expression of PTEN to affect the radiosensitivity, cell growth and invasion of gastric cancer SGC7901 cells. When miR-222 was downregulated, the malignant behavior of SGC7901 cells was significantly inhibited, suggesting that miR-222 may play a role as oncogene in gastric cancer ([@b27-ol-0-0-8815]). Different expression levels of miRNA were observed in uterus cancer tissues with the different differentiation degrees. The expression level of miR-222 in grade III uterine cancer was obviously higher than that in grade I and II. The expression level of miR-222 was increased with the increased degree of malignancy. Therefore, we speculate that miR-222 expression upregulation in uterine cancer may silence downstream tumor suppressor genes such as p27 ([@b28-ol-0-0-8815]), p57 ([@b29-ol-0-0-8815]) and Bmf ([@b30-ol-0-0-8815]). In addition, the expression level of miR-222 was negatively correlated with the survival time of patients with uterine cancer, suggesting that the expression of miR-222 in uterine cancer may serve as an indicator for the prognosis of this disease.

In conclusion, upregulated expression of miR-222 in uterine cancer may play an important role in the occurrence and development of uterine cancer. Our future studies will focus on the function of target genes of miR-222 to identify new targets for the treatment of uterine cancer.
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![Results of 8% PAGE of PCR amplification product of miRNA and endogenous control let-7a. Lanes 1, 2 and 3 are miR-222, let-7a and 50 bp DNA markers, respectively. Results show that stem-loop RT-PCR method can be used to specifically amplify miR-222.](ol-16-02-1722-g00){#f1-ol-0-0-8815}

![Analysis of specificity of miR-222 stem-loop RT-PCR. Lane A, 5 µg of total RNA; lane B, RNA (\<200 nt) isolated from 5 µg of total RNA; lane C, miRNA precursor (60--100 nt) isolated from 5 µg of total RNA by 15% PAGE; lane D, mature miRNA (18--24 nt) isolated from 5 µg of total RNA by 15% PAGE. PCR with 30 cycles provided a faint band of miRNA precursor, while PCR with 22 cycles failed to show this band.](ol-16-02-1722-g01){#f2-ol-0-0-8815}

![Relative expression levels of miR-222 in adjacent and uterine cancer tissues. The expression level of miR-222 in adjacent tissues was significantly lower than that in uterine cancer tissues.](ol-16-02-1722-g02){#f3-ol-0-0-8815}

![Correlation between miR-222 expression and prognosis. The expression level of miR-222 was negatively correlated with the survival of uterine cancer patients.](ol-16-02-1722-g03){#f4-ol-0-0-8815}

###### 

Primers used in stem-loop RT-PCR.

  Primer                  Sequence
  ----------------------- ------------------------------------------------------------
  miR-222                 
  RT stem-loop primer     5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACCCAGTA-3′
  Forward primer          5′-GTTCGTFFFAFCTACATCTGGC-3′
  let-7a                  
  RT stem-loop primer     5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAACTATAC-3′
  Forward primer          5′-ATGGTTCGTGGGTGAGGTAGTAGGTTGT-3′
  Common reverse primer   5′-GTGTCGTGGAGTCGGCAATTC-3′

###### 

Correlation between miR-222 expression and a variety of clinicopathological features of uterine cancer.

  Clinicopathological features    Cases   miR-222 expression   P-value
  ------------------------------- ------- -------------------- ---------
  Age (years)                                                  
    \<40                          17      0.394±0.074          0.916
    40--60                        21      0.371±0.068          
    \>60                          28      0.474±0.085          
  Tumor size (cm)                                              
    \<4                           27      0.527±0.093          0.617
    ≥4                            39      0.416±0.078          
  Gross type                                                   
    Exogenous type                32      0.371±0.064          0.563
    Endogenous type               19      0.398±0.069          
    Ulcer type                    11      0.474±0.086          
    Neck type                       4     0.973±0.184          
  Tissue differentiation                                       
    Large cell keratinizing (I)     9     0.214±0.047          0.001
    Non-Keratinizing type (II)    19      0.289±0.051          
    Small cell type (III)         38      0.656±0.117          
  Pathological type                                            
    Squamous cell carcinoma       53      0.427±0.082          0.628
    Adenocarcinoma                  9     0.416±0.079          
    Adenosquamous carcinoma         4     0.398±0.077          
  FIGO stage                                                   
    Stage I                         6     0.234±0.049          0.284
    Stage II                      25      0.425±0.082          
    Stage III                     18      0.419±0.084          
    Stage IV                      17      0.427±0.087          
